• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

低 Cubilin/髓过氧化物酶比值可作为预测高级别 T1 膀胱癌预后的有前途的生物标志物。

Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.

机构信息

Department of Urology, Central Lisbon University Hospital Centre, Lisbon, Portugal.

Department of Chemistry, Faculty of Science and Technology, Caparica, Portugal.

出版信息

Int Urol Nephrol. 2024 Aug;56(8):2577-2587. doi: 10.1007/s11255-024-03971-4. Epub 2024 Mar 26.

DOI:10.1007/s11255-024-03971-4
PMID:38530585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11266244/
Abstract

PURPOSE

T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker.

METHODS

Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan-Meier curves were used for data analysis.

RESULTS

Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts.

CONCLUSION

This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.

摘要

目的

T1 膀胱癌的进展和复发率较高。在非肌肉浸润阶段识别侵袭性肿瘤对于早期干预至关重要，从而提高患者的生存率。本研究旨在探讨 Cubilin/髓过氧化物酶（CUBN/MPO）比值作为高级别 T1 膀胱癌生物标志物的潜力。

方法

收集了 30 名接受高级别 T1 膀胱癌经尿道肿瘤切除术的患者（2015 年 6 月至 2019 年 12 月）术前的尿液样本。使用高分辨率质谱分析尿液蛋白质组，并计算 CUBN/MPO 比值。主要结局是随访期间的复发（切除后约 31.5 个月）。采用单因素 Cox 回归和 Kaplan-Meier 曲线进行数据分析。

结果

CUBN/MPO 比值低的患者表现出 MPO 上调和/或 CUBN 下调。这组患者疾病复发和进展的发生率更高。低 CUBN/MPO 比值与更高的复发、进展和死亡风险显著相关。值得注意的是，本研究是探索性的，样本量较小，因此需要在更大的队列中进一步研究以验证这些发现。

结论

本研究强调了 CUBN/MPO 比值作为高级别 T1 膀胱癌预后生物标志物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/312fdb60d38f/11255_2024_3971_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/28cdbaed3e61/11255_2024_3971_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/102ebccee4e2/11255_2024_3971_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/4dbba4622d3b/11255_2024_3971_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/312fdb60d38f/11255_2024_3971_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/28cdbaed3e61/11255_2024_3971_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/102ebccee4e2/11255_2024_3971_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/4dbba4622d3b/11255_2024_3971_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e82/11266244/312fdb60d38f/11255_2024_3971_Fig4_HTML.jpg

相似文献

1
Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.低 Cubilin/髓过氧化物酶比值可作为预测高级别 T1 膀胱癌预后的有前途的生物标志物。
Int Urol Nephrol. 2024 Aug;56(8):2577-2587. doi: 10.1007/s11255-024-03971-4. Epub 2024 Mar 26.
2
Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients.对 T1 膀胱癌患者进行蛋白质-蛋白质相互作用的生化网络分析。
J Proteomics. 2023 Apr 30;278:104865. doi: 10.1016/j.jprot.2023.104865. Epub 2023 Mar 2.
3
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术（re-cTURBT）作为pT1期高级别（HG）疾病复发和进展的风险指标是否有用？一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
4
Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.细胞周期标志物并不能提高欧洲癌症研究与治疗组织（EORTC）和CUETO风险模型在预测非肌层浸润性高级别膀胱癌复发和进展方面的鉴别能力。
Urol Oncol. 2016 Nov;34(11):485.e7-485.e14. doi: 10.1016/j.urolonc.2016.05.014. Epub 2016 Sep 13.
5
The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study.T1期高级别膀胱癌二次经尿道切除术的临床意义：一项前瞻性研究的结果
Korean J Urol. 2015 Jun;56(6):429-34. doi: 10.4111/kju.2015.56.6.429. Epub 2015 May 28.
6
Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.经尿道切除术后 T1 期膀胱尿路上皮癌的亚分期对预后的意义。
Am J Surg Pathol. 2012 Mar;36(3):454-61. doi: 10.1097/PAS.0b013e31823dafd3.
7
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.高级别 T1 期与肌层浸润性膀胱癌中 PD-L1 的差异表达及其预后意义。
J Urol. 2017 Oct;198(4):817-823. doi: 10.1016/j.juro.2017.04.102. Epub 2017 May 6.
8
Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer.尿路上皮癌中分化差异对T1期高级别膀胱癌患者肿瘤学结局的影响。
Jpn J Clin Oncol. 2017 Jun 1;47(6):560-567. doi: 10.1093/jjco/hyx030.
9
Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.尿中 let-7c 簇的表达作为一种非侵入性工具，用于评估高级别非肌肉浸润性膀胱癌患者疾病进展的风险：一项初步研究。
J Exp Clin Cancer Res. 2020 Apr 17;39(1):68. doi: 10.1186/s13046-020-01550-w.
10
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.卡介苗诱导治疗后首次评估时膀胱癌的乳头状复发：对临床试验设计的启示
Eur Urol. 2016 Nov;70(5):778-785. doi: 10.1016/j.eururo.2016.02.031. Epub 2016 Feb 24.

本文引用的文献

1
Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics.基于纵向尿液蛋白质组学的膀胱癌病程通路引导监测
Commun Med (Lond). 2023 Jan 16;3(1):8. doi: 10.1038/s43856-023-00238-4.
2
A Liquid Biopsy in Bladder Cancer-The Current Landscape in Urinary Biomarkers.膀胱癌的液体活检——尿液生物标志物的现状。
Int J Mol Sci. 2022 Aug 2;23(15):8597. doi: 10.3390/ijms23158597.
3
Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies.前列腺癌细胞外囊泡蛋白质组学：质谱研究的比较分析。
Int J Mol Sci. 2021 Dec 19;22(24):13605. doi: 10.3390/ijms222413605.
4
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target.髓过氧化物酶：在癌症发病机制中的重要性日益增加及作为潜在药物靶点的潜力。
Pharmacol Ther. 2022 Aug;236:108052. doi: 10.1016/j.pharmthera.2021.108052. Epub 2021 Dec 8.
5
Ultrasonic-Based Filter Aided Sample Preparation as the General Method to Sample Preparation in Proteomics.基于超声的滤过辅助样品制备作为蛋白质组学样品制备的通用方法。
Anal Chem. 2020 Jul 7;92(13):9164-9171. doi: 10.1021/acs.analchem.0c01470. Epub 2020 Jun 11.
6
Proteome-based classification of Nonmuscle Invasive Bladder Cancer.基于蛋白质组学的非肌肉浸润性膀胱癌分类。
Int J Cancer. 2020 Jan 1;146(1):281-294. doi: 10.1002/ijc.32556. Epub 2019 Jul 26.
7
Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease.内因子-维生素 B12 受体在发育和疾病中的 Cubilin
Curr Med Chem. 2020;27(19):3123-3150. doi: 10.2174/0929867325666181008143945.
8
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.手术在转移性膀胱癌中的作用：系统评价。
Eur Urol. 2018 Apr;73(4):543-557. doi: 10.1016/j.eururo.2017.09.030. Epub 2017 Nov 7.
9
The Perseus computational platform for comprehensive analysis of (prote)omics data.Perseus 计算平台，用于全面分析（蛋白质组学）数据。
Nat Methods. 2016 Sep;13(9):731-40. doi: 10.1038/nmeth.3901. Epub 2016 Jun 27.
10
Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.根治性膀胱切除术后原发性和进展性癌侵犯膀胱肌肉的长期预后比较。
BJU Int. 2016 Apr;117(4):604-10. doi: 10.1111/bju.13146. Epub 2015 Jun 3.